More than 1 million prescriptions for the COVID-19 antiviral pills Lagevrio and Paxlovid were dispensed between late December 2021 and May 2022, but dispensing rates were lowest in the most socially and economically disadvantaged communities, according to a study released today by the Centers for Disease Control and Prevention. In a separate study of electronic health records from Kaiser Permanente Southern California over the period, fewer than 1% of patients aged 12 and older who received Paxlovid to treat mild-to-moderate COVID-19 had a COVID-19-related hospitalization or emergency department visit in the next five to 15 days. CDC said the studies “highlight the importance of ensuring access to oral antiviral medicine in treating COVID-19, a key strategy in preventing hospitalization and death.”

Related News Articles

Blog
Since 2018, Black Maternal Health Week has been a national observance from April 11–17. This annual observance was created by the Black Mamas Matter Alliance…
Headline
Women with health-related social needs such as food insecurity, housing instability and lack of transportation were less likely to report receiving a mammogram…
Headline
The Office of Management and Budget March 28 released its final updated standards for Federal agencies on maintaining, collecting and presenting data on race…
Blog
My paternal grandmother was born in 1913 as the youngest of five children and the only girl. She had three sons and no daughters. When I arrived, I was the…
Blog
I was raised by my mother, who was a nurse, and an elder sister, who both prioritized education. During a visit to Kentucky State University, I was inspired to…
Headline
The AHA and other founding members of the Common Health Coalition March 13 committed to action in four priority areas: coordination between health care and…